Clinical Trials

Text Size A A

E-Mail to a Friend

secret  Click to Play Audio

Studies for Newly Diagnosed Lung Cancer


Safety and Tolerability of Nivolumab (BMS-936558) for Non-small Cell Lung Cancer (UW11037)
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab maintenance, Erlotinib, Ipilimumab or monotherapy in First line or in Switch Maintenance in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)

Investigator: Laura Q.M. Chow, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01454102

CO-1686 vs. Erlotinib for Non-Small Cell Lung Cancer (UW14055)
TIGER 1: A Randomized, Open-Label, Phase 2 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced NSCLC

Investigator: ;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02186301

Photon Therapy Vs. Proton Therapy for Non-small Cell Lung Cancer (RTOG 1308)
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC

Investigator: Ramesh Rengan, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01993810

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Investigator: Renato G. Martins, MD;   Conditions: Lung Cancer;    Status: Pending;   Study ID: NCT02194738